DOCSLIB.ORG

Ligand Functional Selectivity Advances Our Understanding of Drug

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ligand Functional Selectivity Advances Our Understanding of Drug HOT TOPICS ............................................................................................................................................................... 345 which continues to the end of the reach only up to 7–10 years of except for income received from their second decade, can, potentially, cause ageFtoo early to characterize long- primary employers, no financial sup- enduring, functionally significant term outcomes. port or compensation has been changes in neuronal circuitry. The Early-life experience and environ- received from any individual or cor- duration and timing of drug treatment mental factors are emerging as addi- porate entity over the past 3 years for are critical in determining long-term tional, important modulators of the research or professional service effects (Popa et al, 2008), owing to effects of psychotropic medications. and there are no personal financial developmental changes in the neural We recently showed that, in rats, some holdings that could be perceived as substrates on which the drugs act. of the enduring behavioral conse- constituting a potential conflict of Stress, which is associated with quences of fetal exposure to fluoxetine interest. affective disorders, adversely impacts do not occur if exposed infants are Douglas O Frost1, Robbin Gibb2 and neural development during fetal life subjected to behavioral testing, Bryan Kolb2 and postnatally, and is ameliorated by which, by its nature, provides supple- 1Department of Pharmacology and Experimental therapies that improve affect. Thus, mental sensory stimulation and Therapetics, Program in Neuroscience, University of Maryland School of Medicine, Baltimore, MD, USA; potential, adverse, long-term effects of exercise (R Gibb, DO Frost and B 2Canadian Center for Behavioral Neuroscience, exposing the developing brain to Kolb, unpublished data). A provoca- University of Lethbridge, Lethbridge, AB, Canada medication must be weighed against tive, parallel finding has recently been E-mail: [email protected] the deleterious impact of stress eleva- reported in humans: In infants who ..................................................................... tion as a result of interrupted phar- are not breast fed, maternal SSRI use Ansorge MS, Morelli E, Gingrich JA (2008). Inhibition macotherapy of pregnant women, or during pregnancy is associated with of serotonin but not norepinephrine transport during development produces delayed, persistent not treating children or adolescents. altered hypothalamo–pituitary–adre- perturbations of emotional behaviors in mice. Human studies have revealed few nal (HPA) stress responses, whereas J Neurosci 28: 199–207. effects of fetal antidepressant drug breast feeding abolishes this effect of Depino AM, Tsetsenis T, Gross C (2008). GABA homeostasis contributes to the developmental (ADD) exposure that endure beyond fetal SSRI exposure by 3 months of age programming of anxiety-related behavior. Brain infancy. By contrast, adult rodents (Oberlander et al, 2008). The mode of Res 1210: 189–199. exposed to ADDs only during stages feeding seems to act epigenetically: Frost DO, Cercio Page S, Carroll C, Kolb B (2009). Early exposure to haloperidol or olanzapine in- corresponding to fetal life, childhood, breast-fed infants have lower methyla- duces long term alterations of dendritic form. or adolescence in humans exhibit a tion (and probably higher expression) Synapse (in press). spectrum of abnormalities, many of of the glucocorticoid receptor gene Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM (2008). Prenatal exposure to which are, surprisingly, components NR3C1 than nonbreast-fed infants maternal depression, neonatal methylation of of depression. Similar, long-term, (Oberlander et al, 2008). human glucocorticoid receptor gene (NR3C1) ‘mirror image’ effects (that is, Animal and human studies are and infant cortisol stress responses. Epigenetics 3: 97–106. drug-induced increases in disease consistent in demonstrating that Popa D, Lena C, Alexandre C, Adrien J components that are reduced by environment and experience during (2008). Lasting syndrome of depression pro- pharmacological treatment of adults) fetal and postnatal brain maturation duced by reduction in serotonin uptake dur- ing postnatal development: evidence from occur after early-life anxiolytic treat- interact with early-life psychotropic sleep, stress, and behavior. J Neurosci 28: ment (Depino et al, 2008). Early drug exposure to shape the ontogeny 3546–3554. exposure to atypical antipsychotic of behavior and neural circuitry. Zuo J, Liu Z, Ouyang X, Liu H, Hao Y, Xu L et al (2008). Distinct neurobehavioral consequences of drugs, used to treat bipolar disorder Epigenetic modulation of gene expres- prenatal exposure to sulpiride (SUL) and risper- in children and adolescents, induces sion appears to be one important idone (RIS) in rats. Prog Neuropsychopharmacol significant, long-lasting cognitive mediator of these effects. These find- Biol Psychiatry 32: 387–397. deficits (Zuo et al, 2008) and morpho- ings suggest possibilities for designing Neuropsychopharmacology Reviews (2010) 35, logical abnormalities (Frost et al, new therapeutic strategies that miti- 344–345; doi:10.1038/npp.2009.133 2009). gate the effects of early-life ADD Why do rodent and human data exposure. seem discrepant? In rodents, the behavioral syndromes induced by ACKNOWLEDGEMENTS early ADD (Ansorge et al, 2008) or Ligand functional anxiolytic (Depino et al, 2008) treat- This work was funded by 5R01 selectivity advances our ment are progressive and emerge fully MH074083 from the National Insti- understanding of drug only in early adulthood. This is tutes of Health, a Research Enhance- because early-life brain insults induce ment Award Program from the mechanisms and drug a cascade of effects over the course of Research Service of the US Depart- discovery development. Human studies of the ment of Veterans Affairs to DOF and effects on progeny of maternal ADD the Canadian Institutes of Health ‘Intrinsic efficacy’ (the concept that a treatment during pregnancy so far Research (BK). We declare that, drug acting at a single receptor is .............................................................................................................................................. Neuropsychopharmacology ............................................................................................................................................................... HOT TOPICS 346 always an agonist, partial agonist, or differentiated side-effect profiles of the topic of this commentary. Except for his primary employment, Dr Vishakantha Murthy declares that no antagonist/inverse agonist) had been functional selectivity. compensation or support has been received from any accepted for a half-century. Two Of direct neuropsychopharmacolo- entity over the past three years for research or decades ago, it became clear that a gical relevance is the dopamine professional service. This work was supported by grants MH040537 and MH082441. single G protein-coupled receptor mechanism of action of aripiprazole. ..................................................................... (GPCR) could have promiscuous The most commonly disseminated Huang XP, Setola V, Yadav PN, Allen JA, Rogan SC, G protein interactions. This suggested hypothesis is that aripiprazole causes Hanson BJ et al (2009). Parallel functional activity that some drugs might cause differ- ‘dopamine stabilization’ through D profiling reveals valvulopathogens are potent 2 5-HT2B receptor agonists: implications for drug ential effects on signaling via a single partial agonism. Conversely, other safety assessment. Mol Pharmacol Online July 1, receptor, and within a few years, there data have shown that aripiprazole, 2009; doi:10.1124/mol.109.058057. were data showing such ‘anomalous’ although sometimes a partial agonist, Kilts JD, Connery HS, Arrington EG, Lewis MM, F Lawler CP, Oxford GS et al (2002). Functional functional responses in the extreme, can also be a D2 pure antagonist or full selectivity of dopamine receptor agonists. II. a ligand acting at a single receptor agonist depending on the assay sys- Actions of dihydrexidine in D2L receptor-trans- being a full agonist at one function tem. As we have reviewed recently fected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther 301: 1179–1189. and an antagonist at another (Kilts (Mailman, 2007), the original in vivo/ Mailman RB (2007). GPCR functional selectivity has et al, 2002). ex vivo data from the drug’s disco- therapeutic impact. Trends Pharmacol Sci 28: Strikingly, most laboratories engaged verers are consistent with D func- 390–396. 2 Neve KA (2009). Functional Selectivity of G Protein- with this phenomenon recognized its tional selectivity, but not with simple Coupled Receptor Ligands. Humana: New York. implications, each proffering a unique partial agonism. Functional selectivity Smith HP, Nichols DE, Mailman RB, Lawler CP name (eg, agonist-directed trafficking would thus predict that D ligands (1997). Locomotor inhibition, yawning and vacu- 2 ous chewing induced by a novel dopamine D2 of signaling, biased agonism, etc), with selected as partial agonists in a single post-synaptic receptor agonist. Eur J Pharmacol functional selectivity emerging as common functional assay may not be 323: 27–36. the apparent consensus. The naming similar clinically. From this perspec- Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H et al (2007). Func-
Load more

Recommended publications
  • The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus Lee A
    The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus Lee A. Dawson, Ph.D., Huy Q. Nguyen, B.S., and Ping Li, B.S. Preclinical evidence has suggested a possible role for the 5-HT6 increases in extracellular glutamate levels in both frontal receptor in the treatment of cognitive dysfunction. However, cortex and dorsal hippocampus, respectively. These effects were currently there is little neurochemical evidence suggesting the completely attenuated by infusion of tetrodotoxin but mechanism(s) which may be involved. Using the selective unaffected by the muscarinic antagonist, atropine. Here we 5-HT6 antagonist SB-271046 and in vivo microdialysis, we demonstrate for the first time the selective enhancement of have evaluated the effects of this compound on the modulation excitatory neurotransmission by SB-271046 in those brain of basal neurotransmitter release within multiple brain regions regions implicated in cognitive and memory function, and of the freely moving rat. SB-271046 produced no change in provide mechanistic evidence in support of a possible basal levels of dopamine (DA), norepinephrine (NE) or 5-HT therapeutic role for 5-HT6 receptor antagonists in the in the striatum, frontal cortex, dorsal hippocampus or nucleus treatment of cognitive and memory dysfunction. accumbens. Similarly, this compound had no effect on [Neuropsychopharmacology 25:662–668, 2001] excitatory neurotransmission in the striatum or nucleus © 2001 American College of Neuropsychopharmacology. accumbens. Conversely, SB-271046 produced 3- and 2-fold Published by Elsevier Science Inc. KEY WORDS: 5-HT6 receptor; SB-271046; Microdialysis; sma et al. 1993; Ruat et al.
    [Show full text]
  • M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Defic
    M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Deficits in Sprague–Dawley and Wistar Rats Geoffrey B. Varty, Ph.D., Vaishali P. Bakshi, Ph.D., and Mark A. Geyer, Ph.D. a In a recent study using Wistar rats, the serotonergic 5-HT2 1 receptor agonist cirazoline disrupts PPI. As risperidone a receptor antagonists ketanserin and risperidone reduced the and M100907 have affinity at the 1 receptor, a final study disruptive effects of the noncompetitive N-methyl-D- examined whether M100907 would block the effects of aspartate (NMDA) antagonist dizocilpine on prepulse cirazoline on PPI. Risperidone partially, but inhibition (PPI), suggesting that there is an interaction nonsignificantly, reduced the effects of dizocilpine in Wistar between serotonin and glutamate in the modulation of PPI. rats, although this effect was smaller than previously In contrast, studies using the noncompetitive NMDA reported. Consistent with previous studies, risperidone did antagonist phencyclidine (PCP) in Sprague–Dawley rats not alter the effects of dizocilpine in Sprague–Dawley rats. found no effect with 5-HT2 antagonists. To test the hypothesis Most importantly, M100907 pretreatment fully blocked the that strain differences might explain the discrepancy in effect of dizocilpine in both strains; whereas SDZ SER 082 these findings, risperidone was tested for its ability to had no effect. M100907 had no influence on PPI by itself reduce the PPI-disruptive effects of dizocilpine in Wistar and did not reduce the effects of cirazoline on PPI. These and Sprague–Dawley rats. Furthermore, to determine studies confirm the suggestion that serotonin and glutamate which serotonergic receptor subtype may mediate this effect, interact in modulating PPI and indicate that the 5-HT2A the 5-HT2A receptor antagonist M100907 (formerly MDL receptor subtype mediates this interaction.
    [Show full text]
  • Function-Related Dynamics in Multi-Spanning Helical Membrane Proteins Revealed by Solution NMR
    membranes Review Function-Related Dynamics in Multi-Spanning Helical Membrane Proteins Revealed by Solution NMR Koh Takeuchi 1,* , Yutaka Kofuku 2, Shunsuke Imai 3, Takumi Ueda 2, Yuji Tokunaga 1, Yuki Toyama 2 , Yutaro Shiraishi 3 and Ichio Shimada 2,3,* 1 Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Aomi, Koto, Tokyo 135-0064, Japan; [email protected] 2 Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo, Bunkyo, Tokyo 113-0033, Japan; [email protected] (Y.K.); [email protected] (T.U.); [email protected] (Y.T.) 3 Center for Biosystems Dynamics Research, RIKEN, Suehiro, Tsurumi, Yokohama 230-0045, Japan; [email protected] (S.I.); [email protected] (Y.S.) * Correspondence: [email protected] (K.T.); [email protected] (I.S.) Abstract: A primary biological function of multi-spanning membrane proteins is to transfer informa- tion and/or materials through a membrane by changing their conformations. Therefore, particular dynamics of the membrane proteins are tightly associated with their function. The semi-atomic resolution dynamics information revealed by NMR is able to discriminate function-related dynamics from random fluctuations. This review will discuss several studies in which quantitative dynamics information by solution NMR has contributed to revealing the structural basis of the function of multi-spanning membrane proteins, such as ion channels, GPCRs, and transporters. Citation: Takeuchi, K.; Kofuku, Y.; Keywords: membrane protein; NMR; ion channel; GPCR; transporter; dynamics Imai, S.; Ueda, T.; Tokunaga, Y.; Toyama, Y.; Shiraishi, Y.; Shimada, I.
    [Show full text]
  • Early-Life Experience, Epigenetics, and the Developing Brain
    Neuropsychopharmacology REVIEWS (2015) 40, 141–153 & 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 REVIEW ............................................................................................................................................................... www.neuropsychopharmacologyreviews.org 141 Early-Life Experience, Epigenetics, and the Developing Brain 1 ,1 Marija Kundakovic and Frances A Champagne* 1Department of Psychology, Columbia University, New York, NY, USA Development is a dynamic process that involves interplay between genes and the environment. In mammals, the quality of the postnatal environment is shaped by parent–offspring interactions that promote growth and survival and can lead to divergent developmental trajectories with implications for later-life neurobiological and behavioral characteristics. Emerging evidence suggests that epigenetic factors (ie, DNA methylation, posttranslational histone modifications, and small non- coding RNAs) may have a critical role in these parental care effects. Although this evidence is drawn primarily from rodent studies, there is increasing support for these effects in humans. Through these molecular mechanisms, variation in risk of psychopathology may emerge, particularly as a consequence of early-life neglect and abuse. Here we will highlight evidence of dynamic epigenetic changes in the developing brain in response to variation in the quality of postnatal parent–offspring interactions. The recruitment of epigenetic pathways for the
    [Show full text]
  • Gs- Versus Golf-Dependent Functional Selectivity Mediated by the Dopamine D1 Receptor
    ARTICLE DOI: 10.1038/s41467-017-02606-w OPEN Gs- versus Golf-dependent functional selectivity mediated by the dopamine D1 receptor Hideaki Yano1, Ning-Sheng Cai1, Min Xu1, Ravi Kumar Verma1, William Rea1, Alexander F. Hoffman1, Lei Shi1, Jonathan A. Javitch2,3, Antonello Bonci1 & Sergi Ferré1 The two highly homologous subtypes of stimulatory G proteins Gαs (Gs) and Gαolf (Golf) display contrasting expression patterns in the brain. Golf is predominant in the striatum, while 1234567890():,; Gs is predominant in the cortex. Yet, little is known about their functional distinctions. The dopamine D1 receptor (D1R) couples to Gs/olf and is highly expressed in cortical and striatal areas, making it an important therapeutic target for neuropsychiatric disorders. Using novel drug screening methods that allow analysis of specific G-protein subtype coupling, we found that, relative to dopamine, dihydrexidine and N-propyl-apomorphine behave as full D1R agonists when coupled to Gs, but as partial D1R agonists when coupled to Golf. The Gs/Golf- dependent biased agonism by dihydrexidine was consistently observed at the levels of cel- lular signaling, neuronal function, and behavior. Our findings of Gs/Golf-dependent functional selectivity in D1R ligands open a new avenue for the treatment of cortex-specific or striatum- specific neuropsychiatric dysfunction. 1 National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA. 2 Department of Psychiatry, College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA. 3 Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA. Correspondence and requests for materials should be addressed to H.Y.
    [Show full text]
  • Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity Kelly A
    International Journal of Neuropsychopharmacology (2018) 21(10): 962–977 doi:10.1093/ijnp/pyy071 Advance Access Publication: August 6, 2018 Review review Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity Kelly A. Berg and William P. Clarke Department of Pharmacology, University of Texas Health, San Antonio, Texas. Correspondence: William P. Clarke, PhD, Department of Pharmacology, Mail Stop 7764, UT Health at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229 ([email protected]). Abstract Constitutive receptor activity/inverse agonism and functional selectivity/biased agonism are 2 concepts in contemporary pharmacology that have major implications for the use of drugs in medicine and research as well as for the processes of new drug development. Traditional receptor theory postulated that receptors in a population are quiescent unless activated by a ligand. Within this framework ligands could act as agonists with various degrees of intrinsic efficacy, or as antagonists with zero intrinsic efficacy. We now know that receptors can be active without an activating ligand and thus display “constitutive” activity. As a result, a new class of ligand was discovered that can reduce the constitutive activity of a receptor. These ligands produce the opposite effect of an agonist and are called inverse agonists. The second topic discussed is functional selectivity, also commonly referred to as biased agonism. Traditional receptor theory also posited that intrinsic efficacy is a single drug property independent of the system in which the drug acts. However, we now know that a drug, acting at a single receptor subtype, can have multiple intrinsic efficacies that differ depending on which of the multiple responses coupled to a receptor is measured.
    [Show full text]
  • When Simple Agonism Is Not Enough: Emerging Modalities of GPCR Ligands Nicola J
    When simple agonism is not enough: emerging modalities of GPCR ligands Nicola J. Smith, Kirstie A. Bennett, Graeme Milligan To cite this version: Nicola J. Smith, Kirstie A. Bennett, Graeme Milligan. When simple agonism is not enough: emerging modalities of GPCR ligands. Molecular and Cellular Endocrinology, Elsevier, 2010, 331 (2), pp.241. 10.1016/j.mce.2010.07.009. hal-00654484 HAL Id: hal-00654484 https://hal.archives-ouvertes.fr/hal-00654484 Submitted on 22 Dec 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Accepted Manuscript Title: When simple agonism is not enough: emerging modalities of GPCR ligands Authors: Nicola J. Smith, Kirstie A. Bennett, Graeme Milligan PII: S0303-7207(10)00370-9 DOI: doi:10.1016/j.mce.2010.07.009 Reference: MCE 7596 To appear in: Molecular and Cellular Endocrinology Received date: 15-1-2010 Revised date: 15-6-2010 Accepted date: 13-7-2010 Please cite this article as: Smith, N.J., Bennett, K.A., Milligan, G., When simple agonism is not enough: emerging modalities of GPCR ligands, Molecular and Cellular Endocrinology (2010), doi:10.1016/j.mce.2010.07.009 This is a PDF file of an unedited manuscript that has been accepted for publication.
    [Show full text]
  • Mechanism of Action of Antidepressants and Mood Stabilizers
    79 MECHANISM OF ACTION OF ANTIDEPRESSANTS AND MOOD STABILIZERS ROBERT H. LENOX ALAN FRAZER Bipolar disorder (BPD), the province of mood stabilizers, the more recent understanding that antidepressants share has long been considered a recurrent disorder. For more this property in UPD have focused research on long-term than 50 years, lithium, the prototypal mood stabilizer, has events, such as alterations in gene expression and neuroplas- been known to be effective not only in acute mania but ticity, that may play a significant role in stabilizing the clini- also in the prophylaxis of recurrent episodes of mania and cal course of an illness. In our view, behavioral improvement depression. By contrast, the preponderance of past research and stabilization stem from the acute pharmacologic effects in depression has focused on the major depressive episode of antidepressants and mood stabilizers; thus, both the acute and its acute treatment. It is only relatively recently that and longer-term pharmacologic effects of both classes of investigators have begun to address the recurrent nature of drugs are emphasized in this chapter. unipolar disorder (UPD) and the prophylactic use of long- term antidepressant treatment. Thus, it is timely that we address in a single chapter the most promising research rele- vant to the pharmacodynamics of both mood stabilizers and MOOD STABILIZERS antidepressants. As we have outlined in Fig. 79.1, it is possible to charac- The term mood stabilizer within the clinical setting is com- terize both the course and treatment of bipolar and unipolar monly used to refer to a class of drugs that treat BPD.
    [Show full text]
  • Membrane Selectivity by W-Tagging of Antimicrobial Peptides
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1808 (2011) 1081–1091 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbamem Membrane selectivity by W-tagging of antimicrobial peptides Artur Schmidtchen a, Lovisa Ringstad b, Gopinath Kasetty a, Hiroyasu Mizuno c, Mark W. Rutland c, Martin Malmsten b,⁎ a Division of Dermatology and Venereology, Department of Clinical Sciences, Lund University, SE-221 84 Lund, Sweden b Department of Pharmacy, Uppsala University, SE-75123, Uppsala, Sweden c Division of Surface and Corrosion Science, Royal Institute of Technology, SE-10044 Stockholm, Sweden article info abstract Article history: A pronounced membrane selectivity is demonstrated for short, hydrophilic, and highly charged antimicrobial Received 8 October 2010 peptides, end-tagged with aromatic amino acid stretches. The mechanisms underlying this were investigated Received in revised form 16 December 2010 by a method combination of fluorescence and CD spectroscopy, ellipsometry, and Langmuir balance Accepted 20 December 2010 measurements, as well as with functional assays on cell toxicity and antimicrobial effects. End-tagging with Available online 28 December 2010 oligotryptophan promotes peptide-induced lysis of phospholipid liposomes, as well as membrane rupture Keywords: and killing of bacteria and fungi. This antimicrobial potency is accompanied by limited toxicity for human AMP epithelial cells and low hemolysis. The functional selectivity displayed correlates to a pronounced selectivity Antimicrobial peptide of such peptides for anionic lipid membranes, combined with a markedly reduced membrane activity in the Ellipsometry presence of cholesterol.
    [Show full text]
  • Neuropsychopharmacology (2015) 40, 2853–2855 © 2015 American College of Neuropsychopharmacology
    Neuropsychopharmacology (2015) 40, 2853–2855 © 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org Commentary Neuropsychopharmacology: Reflections on 40 Volumes Alan Frazer*,1 1 Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA Neuropsychopharmacology (2015) 40, 2853–2855; doi:10.1038/npp.2015.290 This issue completes volume 40 of Neuropsychopharmaco- methodology has not followed in concert with pre-clinical logy (NPP), with the first issue published in December, 1987. advances such that most efficacy studies still lump together This should be distinguished from our 40th anniversary; what are heterogeneous groups of patients. One might say for the first several years, issues were thin, months were how can we subdivide in the absence of biomarkers, which skipped, and multiple volumes were published per year. To do not exist? But one might also ask how can we hope to find commemorate this accomplishment, the editor-in-chief a biomarker among a group of patients that might have 3, 7, (Dr Carlezon) asked me as in-coming ACNP President to or 10 different pathologies, all leading to the same behavioral write a brief overview of my views on the developments in output. Talk about the chicken and the egg! our field over this time period, using highly cited articles Another theme that continues into the present is the time- published in NPP as a guide. dependent, downstream consequences of acute actions of Early on, two articles highlight themes that continue today. some type of psychotherapeutic drugs that correlate better One is the development of animal models for psychiatric with optimal clinical improvement.
    [Show full text]
  • Pharmacogenomics: the Promise of Personalized Medicine for CNS Disorders
    Neuropsychopharmacology REVIEWS (2009) 34, 159–172 & 2009 Nature Publishing Group All rights reserved 0893-133X/09 $30.00 REVIEW ............................................................................................................................................................... www.neuropsychopharmacology.org 159 Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders Jose de Leon*,1,2,3,4 1 2 Mental Health Research Center, Eastern State Hospital, University of Kentucky, Lexington, KY, USA; College of Medicine, 3 4 University of Kentucky, Lexington, KY, USA; College of Pharmacy, University of Kentucky, Lexington, KY, USA; Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, Medical School, University of Granada, Granada, Spain This review focuses first on the concept of pharmacogenomics and its related concepts (biomarkers and personalized prescription). Next, the first generation of five DNA pharmacogenomic tests used in the clinical practice of psychiatry is briefly reviewed. Then the possible involvement of these pharmacogenomic tests in the exploration of early clinical proof of mechanism is described by using two of the tests and one example from the pharmaceutical industry (iloperidone clinical trials). The initial attempts to use other microarray tests (measuring RNA expression) as peripheral biomarkers for CNS disorders are briefly described. Then the challenge of taking pharmacogenomic tests (compared to drugs) into clinical practice is explained by focusing on regulatory
    [Show full text]
  • Before They Called It Psychopharmacology* Heinz E
    NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO. 4 291 SPECIAL LECTURE Before They Called It Psychopharmacology* Heinz E. Lehmann, M.D. BEFORE THEY CALLED IT Johns Hopkins, who called the domain of psychophar­ PSYCHOPHARMACOLOGY macology "certainly very meager." Macht conducted pharmacologic experiments with opium narcotics and It is a great privilege and honor to be here today, giv­ coal tar analgesics on reaction time, tapping speed, etc., ing the second annual lecture on the history of psy­ much as Kraepelin as early as 1883 had done in Wundt's chopharmacology. My friend Frank Ayd did such an laboratory with alcohol and caffeine, calling it then Phar­ admirable job with his lecture last year, on the early macopsychologie (Macht 1920). history, that I have had a hard problem finding gaps W. Freeman, in 1931, wrote a more general paper to fill. What I have finally chosen to do is to trace for in the Journal of the American Medical Association on you some of the early history, complete with anecdotes, what he called psychochemistry, and in 1935 Thorner which preceded our modern notions of psychology and wrote the fIrst paper resembling our modern concept pharmacology and then to tell you something of my of the term with "Psychopharmacology of Sodium own experiences and findings in the psychiatric world Amytal in Catatonia." I will discuss this paper in more of the 1940s and 1950s, a world that was remarkably detail later . After a careful search of the modern litera­ different and simplistic compared to today. I also in­ ture, I came to the conclusion that official general use tend to give you a subjective "oral history" of my own of the term psychopharmacology in publications dates stumbling attempts to make some sense out of the only to 1960, following a paper by Ross and Cole enti­ vague and somewhat chaotic potpourri of ideas and tled "Psychopharmacology," when also psychophar­ pharmacologic approaches to psychiatric problems a macology appears for the fIrst time as a free-standing half century ago.
    [Show full text]